Characteristics of Patients
| Characteristic . | Short (N = 119) . | Extended (n = 120) . |
|---|---|---|
| Age distribution | ||
| 0-14:15-29:30-39:40-49:50-59:60-69:70+ | 6:28:21:31:19:11:3 | 8:27:21:31:18:12:3 |
| Male/female | 61/58 | 59/61 |
| Performance score | ||
| 0:1:2:3:4 | 37:42:21:14:5 | 36:42:26:13:3 |
| De novo/secondary* | 113/6 | 111/9 |
| WBC ×109/L:0-9.9/10.0+/not known | 79/36/4 | 89/29/2 |
| Cytogenetics/molecular/diagnosis | ||
| t(15:17) alone | 59 | 58 |
| t(15:17) plus other | 34 | 36 |
| t(15:17) molecular | 14 | 15 |
| Chemotherapy protocol | ||
| AML 10/12:DAT/ADE/MAE | 25/49/25 | 24/52/24 |
| AML11: DAT/ADE/MAC | 4/5/11 | 3/5/12 |
| G-CSF/placebo | 19/23 | 24/24 |
| Characteristic . | Short (N = 119) . | Extended (n = 120) . |
|---|---|---|
| Age distribution | ||
| 0-14:15-29:30-39:40-49:50-59:60-69:70+ | 6:28:21:31:19:11:3 | 8:27:21:31:18:12:3 |
| Male/female | 61/58 | 59/61 |
| Performance score | ||
| 0:1:2:3:4 | 37:42:21:14:5 | 36:42:26:13:3 |
| De novo/secondary* | 113/6 | 111/9 |
| WBC ×109/L:0-9.9/10.0+/not known | 79/36/4 | 89/29/2 |
| Cytogenetics/molecular/diagnosis | ||
| t(15:17) alone | 59 | 58 |
| t(15:17) plus other | 34 | 36 |
| t(15:17) molecular | 14 | 15 |
| Chemotherapy protocol | ||
| AML 10/12:DAT/ADE/MAE | 25/49/25 | 24/52/24 |
| AML11: DAT/ADE/MAC | 4/5/11 | 3/5/12 |
| G-CSF/placebo | 19/23 | 24/24 |
Eleven patients had chemotherapy for prior malignancy; 4 had prior hematological disorders (3 MDS and 1 NHL).